Patents Examined by Richard L. Raymond
  • Patent number: 7166590
    Abstract: A compound of the formula (I): [wherein R1 is (substituted) alkyl, alkoxy, phenyl, hetero ring etc.; A is bond, CO, SO2; R2 is H, (substituted) alkyl etc.; D is alkylene etc.; E is COO, OCO, O, S, SO, SO2 etc.; R3 is (substituted) alkyl, carbocyclic ring, hetero ring; J is O, NR16 (R16 is H, substituted alkyl); R4 is (substituted) alkyl, carbocyclic ring, hetero ring.] or non-toxic salt thereof, and an N-type calcium channel blocker comprising it as an active ingredient. The compounds of the formula (I) possess an inhibitory action on N-type calcium channel, so they are useful as agent for the prevention and/or treatment of cerebral infarct, transient ischemic attack, encephalomyelopathy after cardiac operation, spinal angiopathy, hypertension with stress, neurosis or epilepsy etc. or agent for the treatment of pain.
    Type: Grant
    Filed: May 28, 2002
    Date of Patent: January 23, 2007
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Takuya Seko, Masashi Kato
  • Patent number: 7122544
    Abstract: Compounds having activity as inhibitors of IKK are disclosed, particularly IKK-2. The compounds of this invention are anilinopyrimidine derivatives having the following structure: wherein R1 and R6 are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to IKK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.
    Type: Grant
    Filed: December 4, 2001
    Date of Patent: October 17, 2006
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Adam Kois, Karen J. MacFarlane, Yoshitaka Satoh, Shripad S. Bhagwat, Jason S. Parnes, Moorthy S. S. Palanki, Paul E. Erdman
  • Patent number: 7122535
    Abstract: A method of treating pain in a warm-blooded animal comprising administering to anwarm-blooded animal in need thereof an amount of a compound of the formula wherein the substituents are defined in accordance with the disclosure.
    Type: Grant
    Filed: July 26, 2004
    Date of Patent: October 17, 2006
    Assignee: Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.)
    Inventors: Pierre Etienne Chabrier de Lassauniere, Serge Auvin, Dennis Bigg, Michel Auquet, Jeremiah Harnett
  • Patent number: 7122534
    Abstract: The present invention relates to compounds of formula (I) and their pharmaceutically acceptable salts, wherein R1, R2, R3 and Z are as defined herein, intermediates in the synthesis of such compounds, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of neurological and psychological disorders.
    Type: Grant
    Filed: January 23, 2004
    Date of Patent: October 17, 2006
    Assignee: Pfizer Inc
    Inventor: Jotham Wadsworth Coe
  • Patent number: 7119092
    Abstract: wherein R represents a halogen atom or a C1-4 alkyl group; R1 represents a C1-4 alkyl group; R2 represents hydrogen or a C1-4 alkyl group; R3 represents hydrogen, or a C1-4 alkyl group; R4 represents a trifluoromethyl group; R5 represents hydrogen, a C1-4 alkyl group or C(O)R6; R6 represents C1-4 alkyl, C3-7 cycloalkyl, NH(C1-4 alkyl) or N(C1-4alkyl)2; m is zero or an integer from 1 to 3; n is an integer from 1 to 3 and pharmaceutically acceptable salts and solvates thereof; to processes for their preparation and their use in the treatment of conditions mediated by tachykinins.
    Type: Grant
    Filed: October 12, 2001
    Date of Patent: October 10, 2006
    Assignee: SmithKline Beecham Corporation
    Inventors: Giuseppe Alvaro, Paolo Maragni, Marsia Tampieri
  • Patent number: 7109228
    Abstract: This invention relates to pyrazole derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivatives thereof, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such, the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodificiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).
    Type: Grant
    Filed: April 5, 2002
    Date of Patent: September 19, 2006
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Lyn Howard Jones, Charles Eric Mowbray, David Anthony Price, Matthew Duncan Selby, Paul Anthony Stupple
  • Patent number: 7105668
    Abstract: Quinazolinones of formulae 1a, 1b, 1c and 1d are disclosed. They are useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: September 12, 2006
    Assignee: Cytokinetics, Inc.
    Inventors: Gustave Bergnes, Whitney W. Smith, John C. Chabala
  • Patent number: 7101910
    Abstract: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.
    Type: Grant
    Filed: June 12, 2002
    Date of Patent: September 5, 2006
    Assignee: Wellstat Therapeutics Corporation
    Inventors: Shalini Sharma, Reid W. von Borstel
  • Patent number: 7101868
    Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: April 12, 2004
    Date of Patent: September 5, 2006
    Assignee: Amgen Inc.
    Inventors: Daniel Elbaum, Benny C. Askew, Jr., Shon Booker, Julie Germain, Gregory J. Habgood, Michael Handley, Tae-Seong Kim, Aiwen Li, Nobuko Nishimura, Vinod F. Patel, Chester Chenguang Yuan, Joseph L. Kim, Guolin Cai, Guoqing Chen, Michael Croghan, Lucian V. Di Pietro, Celia Dominguez, Qi Huang, Leon M. Smith, II, Andrew Tasker, Ning Xi, Shimin Xu
  • Patent number: 7101867
    Abstract: Compounds represented by the formula: wherein R1 and R2 are hydrogen atom, a hydrocarbon group or a heterocyclic group, or R1 and R2 may form, together with the adjacent carbon atom, a 3- to 8-membered homocyclic or heterocyclic ring, W indicates (i) a group represented by the formula: wherein ring B indicates a 5- to 7-membered ring, or (ii) a group represented by the formula: wherein R4 indicates (1) an aliphatic hydrocarbon group, which may be substituted with an aromatic group, or (2) an acyl group containing an aromatic group, R5 is hydrogen atom, a C1-6 alkyl, or an acyl group, provided that, when W is Wa, R3 is hydrogen atom, a hydrocarbon group or a heterocyclic group, when W is Wb, R3 indicates a C6-14 aryl group, or salts thereof or prodrugs thereof have an excellent action to inhibit neurodegeneration and the like as well as an excellent brain penetrability and are low in the toxicity, thereby being useful as prophylactic or therapeutic drugs for nerve degenerative diseases and the
    Type: Grant
    Filed: April 11, 2002
    Date of Patent: September 5, 2006
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shigenori Ohkawa, Yasuyoshi Arikawa, Kouki Kato, Masahiro Okura, Masaki Setoh
  • Patent number: 7101994
    Abstract: The invention relates to new methods of preparing substituted benzimidazole compounds, such as 2-bromo-5,6-dichlorobenzimidazole, which are useful in the preparation of compounds having antiviral activity.
    Type: Grant
    Filed: April 10, 2001
    Date of Patent: September 5, 2006
    Assignee: SmithKline Beecham Corporation
    Inventor: Stephen Freeman
  • Patent number: 7098201
    Abstract: A compound of the formula (I): wherein X is hydroxy, protected hydroxy or optionally substituted amino; Y is —COORA wherein RA is hydrogen or ester residue, —CONRBRC wherein RB and RC each is independently hydrogen or amide residue, optionally substituted aryl or optionally substituted heteroaryl; and A1 is optionally substituted heteroaryl; provided that a compound wherein Y and/or A1 is optionally substituted indol-3-yl is excluded, a tautomer, a prodrug, a pharmaceutically acceptable salt or a hydrate thereof has an inhibitory activity against an integrase.
    Type: Grant
    Filed: June 18, 2003
    Date of Patent: August 29, 2006
    Assignee: Shionogi & Co., Ltd.
    Inventors: Toshio Fujishita, Tomokazu Yoshinaga, Akihiko Sato
  • Patent number: 7087747
    Abstract: An object of the present invention is to provide a new ?-oxo bridged heterometal compound, which can make the photo-functional materials to have diversified properties, and a production method such that the ?-oxo bridged heterometal compound is obtained simply, selectively and with high yield. The present invention provides ?-oxo bridged heterometal compounds, NcM1-O-M2Nc, PcM1-O-M2Nc and NcM1-O-M2Pc wherein Nc represents naphthalocyanine, Pc represents phthalocyanine, M1 represents a metal atom which is able to have a valence of up to three, and M2 represents a metal atom which is able to have a valence of four or five.
    Type: Grant
    Filed: November 6, 2003
    Date of Patent: August 8, 2006
    Assignee: Orient Chemical Industries, Ltd.
    Inventors: Yasuhiro Yamasaki, Kenji Takaki
  • Patent number: 7074780
    Abstract: The present invention relates to substituted phenylcyclohexanecarboxamides of the formula (I) to processes for their preparation and to their use in medicaments, in particular for the prevention and/or treatment of cardiovascular disorders.
    Type: Grant
    Filed: November 17, 2003
    Date of Patent: July 11, 2006
    Assignee: Bayer Aktiengesellschaft
    Inventors: Erwin Bischoff, Thomas Krahn, Stephan-Nicholas Müller, Holger Paulsen, Joachim Schuhmacher, Henning Steinhagen, Wolfgang Thielemann
  • Patent number: 7074800
    Abstract: The invention relates to the use of compounds of formula (I), wherein ring C is an 8, 9, 10, 12 or 13-membered bicyclic or tricyclic moiety which optionally may contain 1–3 heteroatoms selected independently from O, N and S; Z is —O—, —NH—, —S—, —CH2— or a direct bond; n is 0–5; m is 0–3; R2 represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C1-3alkyl, C1-3alkoxy, C1-3alkylsulphanyl, —NR3R4 (wherein R3 and R4, which may be the same or different, each represents hydrogen or C1-3alkyl), or R5X1— (wherein X1 and R5 are as defined herein; R1 represents hydrogen, oxo, halogeno, hydroxy, C1-4alkoxy, C1-4alkyl, C1-4alkoxymethyl, C1-4alkanoyl, C1-4haloalkyl, cyano, amino, C2-5alkenyl, C2-5alkynyl, C1-3alkanoyloxy, nitro, C1-4alkanoylamino, C1-4alkoxycarbonyl, C1-4alkylsulphanyl, C1-4alkylsulphinyl, C1-4alkylsulphonyl, carbamoyl, N—C1-4alkylcarbamoyl, N,N-di(C1-4alkylcarbamoyl, aminosulphonyl, N—C1-4alkylaminosulphonyl, N,N-di(C1-4alkyl)aminosulphonyl, N—(C1-4alkylsulphonyl)amino, N—(C1-4alkylsulph
    Type: Grant
    Filed: February 8, 2000
    Date of Patent: July 11, 2006
    Assignee: AstraZeneca AB
    Inventors: Elaine S E Stokes, Darren Mckerrecher, Laurent F A Hennequin, Patrick Ple
  • Patent number: 7074925
    Abstract: N-substituted derivatives of 5-oximinobarbituric add of the general formula where X is sulfur; R1 is selected from the group consisting of saturated or unsaturated alkyl, cycloalkyl, aryl and arylalkyl; and R2 is selected from the group consisting of hydrogen, saturated or unsaturated alkyl, cycloalkyl, aryl and arylalkyl possessing a biological activity.
    Type: Grant
    Filed: May 26, 1998
    Date of Patent: July 11, 2006
    Inventor: Rimma Lliinichna Ashkinazi
  • Patent number: 7071180
    Abstract: The invention relates to compounds of the general formula (I): wherein Ar is optionally substituted aryl or heteroaryl; A is (i) —O—, —S—, —SO2—, —NH—, (ii) a C1-4-alkyl- or C1-6-acyl-substituted nitrogen atom or (iii) a C1-8-alkylene chain or a heteroalkylene chain having 2 to 8 chain atoms, which optionally contains at least one unsaturation, and which may be substituted and/or contain a bridge to form a saturated or partially or fully unsaturated ring having 3-8 ring members; B is —C(R4)(R5)—, —OC(R4)(R5)—, —N(R6)C(R4)(R5)—, —N(R6)—, —O—, —S— or —SO2—; R is optionally substituted C3-8-cycloalkyl, aryl or heteroaryl; R1 is (i) a saturated or unsaturated azacyclic or aminoazacyclic ring, or a saturated diazacyclic or aminodiazacyclic ring, which has 4 to 7 ring members, or a saturated aminoazabicyclic, azabicyclic or diazabicyclic ring which has 7 to 10 ring members, which rings optionally are substituted in one or more positions, or a group —[C(R4)(R5)]xN(R2a)(R3a)]; R2a, R3a, R4, R5, R6 and x are as
    Type: Grant
    Filed: June 22, 2004
    Date of Patent: July 4, 2006
    Assignee: Biovitrum AB
    Inventors: Björn Nilsson, Jan Tejbrant, Benjamin Pelcman, Erik Ringberg, Markus Thor, Jonas Nilsson, Mattias Jönsson
  • Patent number: 7071195
    Abstract: Amine and amide derivatives of the formula: which are ligands for the neuropeptide Y Y5 (NPY5) receptor, methods of preparation and pharmaceutical compositions containing amines and amides of formula A as the active ingredient are described. The amines and amides of formula A are useful in the treatment of disorders and diseases associated with NPY receptor subtype Y5.
    Type: Grant
    Filed: February 7, 2002
    Date of Patent: July 4, 2006
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Scott L. Dax, James McNally, Mark Youngman
  • Patent number: 7067506
    Abstract: Aryl- and heteroaryl-substituted urea compounds useful in the treatment of diseases and conditions related to DNA damage or lesions in DNA replication are disclosed. Methods of making the compounds, and their use as therapeutic agents, for example, in treating cancer and other diseases characterized by defects in DNA replication, chromosome segregation, or cell division also are disclosed.
    Type: Grant
    Filed: March 1, 2002
    Date of Patent: June 27, 2006
    Assignee: ICOS Corporation
    Inventors: Kathleen S. Keegan, Edward A. Kesicki, John Joseph Gaudino, Adam Wade Cook, Scott Douglas Cowen, Laurence Edward Burgess
  • Patent number: RE39263
    Abstract: There is disclosed substituted thiocarboxamides of the general formula (I) useful as herbicides.
    Type: Grant
    Filed: December 12, 2003
    Date of Patent: September 5, 2006
    Assignee: Bayer Aktiengesellschaft
    Inventors: Karl-Heinz Linker, Kurt Findeisen, Roland Andree, Mark-Wilhelm Drewes, Andreas Lender, Otto Schallner, Wilhelm Haas, Hans-Joachim Santel, Markus Dollinger